Ghost Tree Capital’s Antares Pharma, Inc. ATRS Stock Holding History

Ghost Tree Capital’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-1,100,000	Closed	-$2.01M	–	87
2014 Q3	$2.01M	Buy	+1,100,000	New	+$2.4M	1.09%	39
2014 Q2	–	Sell	-250,000	Closed	-$875K	–	81
2014 Q1	$875K	Buy	+250,000	New	+$1.11M	0.52%	50

Other funds holding ATRS

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

WHI

William Harris Investors Chicago, Illinois $347M AUM 3.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Ghost Tree Capital's ATRS Position: Q4 2014 in Review

Ghost Tree Capital sold out of Antares Pharma, Inc. (ATRS) in Q4 2014, closing a stake of 1,100,000 shares — an estimated $2.01M sold.

Ghost Tree Capital first reported a position in ATRS in Q1 2014 and held it in 2 quarters. The position peaked at $2.01M in Q3 2014. 87 funds tracked by Wall St. Rank hold ATRS as of Q4 2014.

Ghost Tree Capital reported no remaining Antares Pharma, Inc. position as of Q4 2014 after selling out during the quarter.
Ghost Tree Capital sold 1,100,000 Antares Pharma, Inc. shares in Q4 2014, an estimated $2.01M.
Ghost Tree Capital first reported a position in Antares Pharma, Inc. in Q1 2014 and held it in 2 quarters.
Ghost Tree Capital's Antares Pharma, Inc. position peaked at $2.01M in Q3 2014.
87 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2014.

Based on Ghost Tree Capital's 13F filing for Q4 2014, filed 17 Feb 2015.